

*Zful*

Certification of Mailing or Facsimile Transmission	
I hereby certify that I have reasonable basis to expect that, on the date shown below, this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop _____ Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
Name	Karen L. Pfeiffer
Registration No. (if applicable)	
Signature	<i>Karen L. Pfeiffer</i>
Date	January 12, 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	:	10/770,138
Applicant(s)	:	Paul John Rennie, et al.
Filed	:	February 2, 2004
Title	:	Methods of Preventing and Treating Sars Using Low pH Respiratory Tract Compositions
TC/A.U.	:	1617
Examiner	:	
Conf. No.	:	9660
Docket No.	:	9510
Customer No.	:	27752

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). An Office Action on the merits in the present application has not yet been received. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.


01/18/2005 SSESHE1 00000043 162480 10770138

01 FC:1806 180.00 DA

In accordance with 37 C.F.R. §1.98(a)(2), copies of only foreign patent documents and non-patent literature are enclosed.

Respectfully submitted,

THE PROCTER & GAMBLE COMPANY



Signature

Joan B. Cunningham


Typed or printed name

Registration No. 43,962

(513) 622-3993

Date: January 12, 2005  
Customer No. 29752  
(IDS.doc) (Last Revised 10/06/2004)

Please type a plus sign (+) inside this box → [ + ]



PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 3

### COMPLETE IF KNOWN

Application Number	10/770,138
Confirmation Number	9660
Filing Date	February 2, 2004
First Named Inventor	Paul John Rennie
Group Art Unit	1617
Examiner Name	
Attorney Docket Number	9510

## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	1	US- 4,444,885	04/24/1984	Nakanishi, et al.	
	2	US- 4,552,899	11/12/1985	Sunshine, et al.	
	3	US- 4,619,934	10/28/1986	Sunshine, et al.	
	4	US- 4,689,223	08/25/1987	Arias	
	5	US- 4,767,788	08/30/1988	Diana	
	6	US- 4,826,683	05/02/1989	Bates	
	7	US- 4,828,912	05/09/1989	Hossain, et al.	
	8	US- 4,897,304	01/30/1990	Hossain, et al.	
	9	US- 4,940,728	07/10/1990	Postley	
	10	US- 4,956,385	09/11/1990	Eby, III	
	11	US- RE 33,465	11/27/1990	Eby, III	
	12	US- 5,158,761	10/27/1992	Kamishita, et al.	
	13	US- 5,215,739	06/01/1993	Kamishita, et al.	
	14	US- 5,240,694	08/31/1993	Gwaltney, JR.	
	15	US- 5,252,318	10/12/1993	Joshi, et al.	
	16	US- 5,409,905	04/25/1995	Eby, III	
	17	US- 5,422,097	06/06/1995	Gwaltney, JR	
	18	US- 5,466,680	11/14/1995	Rudy	
	19	US- 5,942,689	02/20/1996	Gwaltney, JR	
	20	US- 5,508,282	04/16/1996	Tulin-Silver, et al.	
	21	US- 5,599,534	02/04/1997	Himmelstein, et al.	
	22	US- 5,622,724	04/22/1997	Bryce-Smith	
	23	US- 5,626,831	05/06/1997	Van Moerkerken	
	24	US- 5,897,872	04/27/1999	Picciano	
	25	US- 6,013,632	01/11/2000	Jones, et al.	
	26	US- 6,080,783	06/27/2000	Davidson, et al.	
	27	US- 6,187,332 B1	02/13/2001	Gern, et al.	
	28	US- 2003/0235550 A1	12/25/2003	Pan, et al.	
	29	US- 2004/0009245 A1	01/15/2004	Vail, III et al.	
EXAMINER			DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO-SB08

(Revised for P&G use 10/8/2003)

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08A (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

JAN 14 2005

PATENT &amp; TRADEMARK OFFICE

Substitute for form 1449A/PTO

## STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 3

## COMPLETE IF KNOWN

Application Number	10/770,138
Confirmation Number	9660
Filing Date	February 2, 2004
First Named Inventor	Paul John Rennie
Group Art Unit	1617
Examiner Name	
Attorney Docket Number	9510

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	30	DE	3431727 A1		03/13/1986	Hempel		X
	31	EP	0046409 A1		02/24/1982	Walliczek		
	32	EP	0310317 A2		04/05/1989	Bordt, et al.		
	33	EP	0371421 A2		06/06/1990	Sehm		
	34	EP	0408330 A2		01/16/1991	Masterson		
	35	EP	0505374 B1		04/23/1997	Deihl		
	36	EP	0856316 A1		08/05/1998	Sawa		
	37	WO	92/20352 A1		11/26/1992	Budorov, et al.		X
	38	WO	94/22428 A1		10/13/1994	Morrey, et al.		
	39	WO	99/44622 A1		09/10/1999	Ormerod, et al.		
	40	WO	03/086408 A1		10/23/2003	Linden, et al.		
	41	WO	03/092654 A1		11/13/2003	Edwards, et al.		
	42	WO	03/094902 A2		11/20/2003	Lin		
	43	WO	03/105775 A2		12/24/2003	Leonard, et al.		
EXAMINER						DATE CONSIDERED		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO-SB08

(Revised for P&amp;G use 10/8/2003)

Please type a plus sign (+) inside this box → [ + ]



PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 3 of 3

### COMPLETE IF KNOWN

Application Number	10/770,138
Confirmation Number	9660
Filing Date	February 2, 2004
First Named Inventor	Paul John Rennie
Group Art Unit	1617
Examiner Name	
Attorney Docket Number	9510

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	44	A. C.W. LAU et al., "Editorial Overview Severe Acute Respiratory Syndrome Treatment: Present Status and Future Strategy", <u>Current Opinion in Investigational Drugs</u> , Vol. 4, No. 8, pp. 918 – 920 (2003).	
	45	GWALTNEY, JR., "Upper Respiratory Infections – The Common Cold", <u>Principles and Practices of Infectious Diseases</u> , 3 <sup>rd</sup> Edition, Published by Churchill Livingstone, Section B, No. 42, pp. 489 – 493, (1990).	
	46	DOUGLAS, et al., "Prophylactic Efficacy of Intranasal Alpha <sub>2</sub> -Interferon Against Rhinovirus Infections in the Family Setting", <u>The New England Journal of Medicine</u> , Vol. 314, No. 2, pp. 65 – 70 (1/9/1986).	
	47	HIGGINS, et al., "A Study of the Efficacy of the Bradykinin Antagonist, NPC 567, in Rhinovirus Infections in Human Volunteers", <u>Antiviral Research</u> , Vol. 14, pp. 339 – 344, (1990).	
	48	FARR, et al., "A Randomized Controlled Trial of Glucocorticoid Prophylaxis against Experimental Rhinovirus Infection", <u>The J. of Infectious Diseases</u> , Vol. 162, pp. 1173 – 1177. (1990).	
	49	BARROW, et al. "The Effect of Intranasal Nedocromil Sodium on Viral Upper Respiratory Tract Infections in Human Volunteers", <u>Clinical and Experimental Allergy</u> , Vol. 20, pp. 45 – 51 (1990).	
	50	GWALTNEY, JR., "Combined Antiviral and Antimediator Treatment of Rhinovirus Colds", <u>The J. of Infectious Diseases</u> , Vol. 166, pp. 776 – 782 (1992).	
	51	POTTER et al., "Dias Rounds: Zinc Lozenges for Treatment of Common Colds", <u>The Annals of Pharmacotherapy</u> , Vol. 27, pp. 589 – 592 (1993).	
	52	ELLIOT, "Influenza Prevention and Treatment – An Update", <u>The Pharmaceutical J.</u> , Vol. 265, pp. 446 – 451 (9/23/2000).	
	53	BELSHE, et al. "Genetic Basis of Resistance of Rimantadine Emerging During Treatment of Influenza Virus Infection", <u>J. of Virology</u> , pp. 1508 – 1512 (5/1998).	
	54	HAY, "The Action of Adamantanamines against influenza A viruses: Inhibition of the M2 ion Channel Protein", <u>Virology</u> , Vol. 3, pp. 21 – 30 (1992).	
	55	MONTO, et al. "Zanamivir in the prevention of Influenza among healthy adults", <u>JAMA</u> , Vol. 282, no. 1, pp. 31 – 35 (7/7/1999).	
	56	TREANOR, et al. "Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza", <u>JAMA</u> , Vol. 283, No. 8, pp. 1016 – 1024 (2/23/2000).	
	57	HUGHES, et al. "Acid Lability of Rhinovirus Type 14: Effect of pH, Time, and Temperature" <u>Proc. Soc. Exp. Biol. Med.</u> , pp. 555 – 560 (1993).	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

PTO-SB08

(Revised for P&G use 10/8/2003)